Meronem Iv

Meropenem, the active ingredient in Meronem Iv, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, septicemia and skin and soft‑tissue infections in hospitalized patients.

GNH USA supplies Meronem Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious Gram‑negative and Gram‑positive bacterial infections.

Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure. Complicated urinary tract infections: resolves infection and prevents recurrence. Nosocomial pneumonia: treats hospital‑acquired lung infection. Septicemia: clears bloodstream infection. Skin and soft tissue infections: eliminates pathogenic bacteria in severe cases.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Headache - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with CNS disorders - Anaphylactic or severe hypersensitivity reactions - Clostridioides difficile‑associated colitis - Severe neutropenia or leukopenia - Acute renal impairment - Hypotension or infusion‑related reactions

Use of Meropenem requires careful clinical assessment and monitoring. - Renal function assessment: adjust dose in renal impairment. - Seizure risk: avoid in patients with pre‑existing CNS disease unless benefits outweigh risk. - β‑lactam allergy: use cautiously in patients with known hypersensitivity. - Superinfection: monitor for secondary infections such as C. difficile. - Neonates: limit use to situations where benefits exceed potential risks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines; awareness of the level of interaction helps manage therapy.

Major Interactions (Avoid): - Valproic acid: carbapenems can markedly reduce serum valproate levels, increasing seizure risk. - Concurrent nephrotoxic agents (e.g., high‑dose aminoglycosides): may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Warfarin: observe INR for potential changes. - Oral contraceptives: possible reduction in contraceptive efficacy; advise alternative contraception. - Phenytoin: may lower phenytoin concentrations. - Probenecid: can increase meropenem plasma levels; adjust dosing if needed.